87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial

BACKGROUND: C5 convertase cleaves C5 in common complement pathways yielding the anaphylatoxin C5a and C5b, part of the membrane attack complex (MAC) that mitigates bacterial infections (Fig 1). C5 can also be cleaved “extrinsically” by other enzymes. C5a is elevated in severe COVID-19 patients (Pt)....

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, Bruce P, Lim, Endry H T, Vlaar, Alexander, De Bruin, Sanne, Brouwer, Matthijs, Habel, Maria, Thielert, Claus, Dickinson, James, Rückinger, simon, Zerbib, Robert, Neukirchen, Dorothee, Guo, Renfeng, van de Beek, Diederik, Riedemann, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677961/
http://dx.doi.org/10.1093/ofid/ofad500.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677961/
http://dx.doi.org/10.1093/ofid/ofad500.003

Ejemplares similares